{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:56:48Z","timestamp":1787021808890,"version":"build-2736575974"},"reference-count":47,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosmentalhealth.org"],"crossmark-restriction":false},"short-container-title":["PLOS Ment Health"],"abstract":"<jats:p>Within the field of psychiatry, the alpha-1 adrenergic antagonist doxazosin is being studied for its off-label uses for disorders involving abnormal sympathetic nervous system arousal, including post-traumatic stress disorder (PTSD) and substance use disorders. Although prazosin is the most well-known alpha-1 antagonist used for these disorders, doxazosin has a longer half-life, which allows for more convenient once-daily dosing. Even though there is an advantage in dosing once daily for doxazosin, the medication is less well-known in the treatment of mental health disorders. The goal of this scoping review is to identify how doxazosin is currently being used in the treatment of mental health disorders, to determine if there is any evidence of its effectiveness for these disorders, and to identify promising areas for further research. PRISMA-ScR guidelines were used to identify articles describing doxazosin for the treatment of mental health disorders in PubMed, Embase, PsycINFO, and CENTRAL to understand current trends in research. Twenty-three articles met the inclusion criteria and included doxazosin for PTSD and\/or nightmares, substance use disorders, and dual diagnoses. Many of the articles were small open-label trials or case reports. Existing evidence is strongest for doxazosin\u2019s use in PTSD-related nightmares and cocaine use disorder, which is consistent with the proposed alpha-1 antagonism effect on disorders with high levels of sympathetic nervous system arousal. Current clinical trials continue to be focused on PTSD and cocaine use disorder, given promising evidence. More randomized controlled trials need to be completed for recommendations of doxazosin\u2019s use for other PTSD hyperarousal symptoms (e.g., flashbacks, intrusive thoughts) and other substance use disorders, including nicotine and alcohol use disorders.<\/jats:p>","DOI":"10.1371\/journal.pmen.0000494","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T18:29:57Z","timestamp":1763576997000},"page":"e0000494","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmen.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Doxazosin for the treatment of mental health disorders: A scoping review"],"prefix":"10.1371","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5528-2904","authenticated-orcid":true,"given":"Christie S.","family":"Richardson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3796-0960","authenticated-orcid":true,"given":"Danah","family":"Atassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1645-4299","authenticated-orcid":true,"given":"Afshan","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3796-0724","authenticated-orcid":true,"given":"Amanda","family":"Bernardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6514-5112","authenticated-orcid":true,"given":"Priyal P.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"key":"pmen.0000494.ref001","year":"1990"},{"key":"pmen.0000494.ref002"},{"key":"pmen.0000494.ref003","volume-title":"Physiology, noradrenergic synapse. In: StatPearls [Internet]. Treasure Island (FL","author":"LS Hussain","year":"2023"},{"key":"pmen.0000494.ref004"},{"issue":"4","key":"pmen.0000494.ref005","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2165\/00003088-198005040-00004","article-title":"Clinical Pharmacokinetics of Prazosin","volume":"5","author":"P Jaillon","year":"1980","journal-title":"Clinical Pharmacokinetics"},{"issue":"2","key":"pmen.0000494.ref006","article-title":"Prazosin for the treatment of nightmares related to posttraumatic stress disorder: a review of the literature","volume":"14","author":"SM Hudson","year":"2012","journal-title":"Prim Care Companion CNS Disord"},{"key":"pmen.0000494.ref007","article-title":"The metabolism and kinetics of doxazosin in man, mouse, rat and dog","author":"B Kaye","year":"1986","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"pmen.0000494.ref008","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1023\/A:1007074420772","article-title":"Inflammatory mediators and modulation of blood-brain barrier permeability","volume":"20","author":"NJ Abbott","year":"2000","journal-title":"Cell Mol Neurobiol"},{"key":"pmen.0000494.ref009","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"MJ Page","year":"2021","journal-title":"BMJ"},{"issue":"5","key":"pmen.0000494.ref010","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.14m09681","article-title":"Doxazosin XL reduces symptoms of posttraumatic stress disorder in veterans with PTSD: a pilot clinical trial","volume":"77","author":"C Rodgman","year":"2016","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"pmen.0000494.ref011","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/JCP.0b013e3181c827ae","article-title":"Doxazosin treatment for posttraumatic stress disorder","volume":"30","author":"J De Jong","year":"2010","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"pmen.0000494.ref012","first-page":"67","article-title":"An Open-Label Study of Doxazosin Extended-Release for PTSD: Findings and Recommendations for Future Research on Doxazosin","volume":"16","author":"A Richards","year":"2018","journal-title":"Focus (Am Psychiatr Publ)"},{"issue":"1","key":"pmen.0000494.ref013","first-page":"26","article-title":"Doxazosin, an \u03b1-1-adrenergic-receptor Antagonist, for Nightmares in Patients with Posttraumatic Stress Disorder and\/or Borderline Personality Disorder: a Chart Review","volume":"50","author":"S Roepke","year":"2017","journal-title":"Pharmacopsychiatry"},{"key":"pmen.0000494.ref014","article-title":"Doxazosin for the treatment of nightmare disorder: A diary-based case study","volume":"8","author":"S Pallesen","year":"2020","journal-title":"SAGE Open Med Case Rep"},{"issue":"2","key":"pmen.0000494.ref015","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1590\/1516-4446-2018-0292","article-title":"Treating nightmares in PTSD with doxazosin: a report of three cases","volume":"41","author":"VC Calegaro","year":"2019","journal-title":"Braz J Psychiatry"},{"issue":"5","key":"pmen.0000494.ref016","article-title":"Doxazosin for the treatment of nightmares: does it really work? A case report","volume":"14","author":"R Sethi","year":"2012","journal-title":"Prim Care Companion CNS Disord"},{"key":"pmen.0000494.ref017","doi-asserted-by":"crossref","first-page":"6452923","DOI":"10.1155\/crps\/6452923","article-title":"Doxazosin Immediate Release as a Novel Treatment for Nightmares in Posttraumatic Stress Disorder","volume":"2024","author":"D Khan","year":"2024","journal-title":"Case Rep Psychiatry"},{"issue":"4","key":"pmen.0000494.ref018","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/YIC.0000000000000364","article-title":"Doxazosin improved COVID-19 associated nightmare in a patient with major depressive disorder: a case report with a positive rechallenge","volume":"36","author":"H Hori","year":"2021","journal-title":"Int Clin Psychopharmacol"},{"issue":"3","key":"pmen.0000494.ref019","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/adb.12611","article-title":"Pharmacogenetics of Dopamine \u03b2-Hydroxylase in cocaine dependence therapy with doxazosin","volume":"24","author":"X Zhang","year":"2019","journal-title":"Addict Biol"},{"key":"pmen.0000494.ref020","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2016.08.420","article-title":"Adrenoceptor variants moderate treatment response of doxazosin for cocaine use disorder","volume":"171","author":"DA Nielsen","year":"2017","journal-title":"Drug and Alcohol Dependence"},{"key":"pmen.0000494.ref021","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.drugalcdep.2012.11.021","article-title":"The alpha-1 adrenergic antagonist doxazosin for treatment of cocaine dependence: A pilot study","volume":"131","author":"D Shorter","year":"2013","journal-title":"Drug Alcohol Depend"},{"key":"pmen.0000494.ref022","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2015.07.378","article-title":"Efficacy and tolerability of doxazosin in psychostimulant-dependent patients","volume":"156","author":"MJ Mancino","year":"2015","journal-title":"Drug and Alcohol Dependence"},{"issue":"2","key":"pmen.0000494.ref023","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030854","article-title":"Noradrenergic \u03b11 Receptor Antagonist Treatment Attenuates Positive Subjective Effects of Cocaine in Humans: A Randomized Trial","volume":"7","author":"TF Newton","year":"2012","journal-title":"PLoS ONE"},{"key":"pmen.0000494.ref024","author":"D Shorter"},{"issue":"3","key":"pmen.0000494.ref025","doi-asserted-by":"crossref","DOI":"10.1002\/hup.2660","article-title":"A preliminary investigation into the effects of doxazosin on cognitive functioning in tobacco-deprived and -satiated smokers","volume":"33","author":"W Roberts","year":"2018","journal-title":"Hum Psychopharmacol"},{"issue":"7","key":"pmen.0000494.ref026","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1177\/0269881117699603","article-title":"Effect of doxazosin on stress reactivity and the ability to resist smoking","volume":"31","author":"TL Verplaetse","year":"2017","journal-title":"J Psychopharmacol"},{"key":"pmen.0000494.ref027","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.drugalcdep.2017.03.016","article-title":"Higher pretreatment blood pressure is associated with greater alcohol drinking reduction in alcohol-dependent individuals treated with doxazosin","volume":"177","author":"CL Haass-Koffler","year":"2017","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"pmen.0000494.ref028","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/adb.12275","article-title":"Role of the \u03b11blocker doxazosin in alcoholism: a proof-of-concept randomized controlled trial","volume":"21","author":"GA Kenna","year":"2015","journal-title":"Addiction Biology"},{"key":"pmen.0000494.ref029","author":"J Curtin"},{"issue":"2","key":"pmen.0000494.ref030","article-title":"A Double-Blind Randomized Controlled Trial of Doxazosin for Co-Occurring PTSD and Alcohol Use Disorder in Veterans","volume":"84","author":"SE Back","year":"2023","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"pmen.0000494.ref031","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1080\/00952990.2019.1674864","article-title":"Doxazosin treatment in cocaine use disorder: pharmacogenetic response based on an alpha-1 adrenoreceptor subtype D genetic variant","volume":"46","author":"DI Shorter","year":"2020","journal-title":"The American Journal of Drug and Alcohol Abuse"},{"key":"pmen.0000494.ref032","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaclp.2022.10.134","article-title":"(132) Less of a Nightmare? A Case Report Comparing Doxazosin and Prazosin for PTSD in the Consultation-Liaison Setting","volume":"63","author":"F Hessel","year":"2022","journal-title":"Journal of the Academy of Consultation-Liaison Psychiatry"},{"key":"pmen.0000494.ref033","doi-asserted-by":"crossref","first-page":"101696","DOI":"10.1016\/j.cont.2024.101696","article-title":"Surprising clinical differences among alpha blockers demonstrated in post-marketing event rates","volume":"12","author":"J Visingardi","year":"2024","journal-title":"Continence"},{"key":"pmen.0000494.ref034","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0002-8703(91)90865-F","article-title":"A double-blind comparative study of doxazosin and prazosin in the treatment of essential hypertension","volume":"121","author":"K Fukiyama","year":"1991","journal-title":"Am Heart J"},{"key":"pmen.0000494.ref035","doi-asserted-by":"crossref","first-page":"111253","DOI":"10.1016\/j.pnpbp.2025.111253","article-title":"Factors impacting prazosin efficacy for nightmares and insomnia in PTSD patients - a systematic review and meta-regression analysis","volume":"136","author":"TP Mendes","year":"2025","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"8","key":"pmen.0000494.ref036","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.biopsych.2006.06.032","article-title":"A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder","volume":"61","author":"MA Raskind","year":"2007","journal-title":"Biol Psychiatry"},{"issue":"9","key":"pmen.0000494.ref037","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1176\/appi.ajp.2013.12081133","article-title":"A Trial of Prazosin for Combat Trauma PTSD With Nightmares in Active-Duty Soldiers Returned From Iraq and Afghanistan","volume":"170","author":"MA Raskind","year":"2013","journal-title":"AJP"},{"issue":"7","key":"pmen.0000494.ref038","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.biopsych.2005.09.023","article-title":"Daytime Prazosin Reduces Psychological Distress to Trauma Specific Cues in Civilian Trauma Posttraumatic Stress Disorder","volume":"59","author":"FB Taylor","year":"2006","journal-title":"Biological Psychiatry"},{"issue":"4","key":"pmen.0000494.ref039","doi-asserted-by":"crossref","first-page":"267","DOI":"10.9740\/mhc.2022.08.267","article-title":"Prazosin dosed 3 times a day to treat flashbacks related to PTSD: A case report","volume":"12","author":"C Richardson","year":"2022","journal-title":"Ment Health Clin"},{"issue":"3","key":"pmen.0000494.ref040","first-page":"19","article-title":"Prazosin and doxazosin for PTSD are underutilized and underdosed","volume":"16","author":"MM Koola","year":"2017","journal-title":"Curr Psychiatry"},{"issue":"4","key":"pmen.0000494.ref041","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1159\/000020315","article-title":"Double-blind trial of the efficacy and tolerability of doxazosin in the gastrointestinal therapeutic system, doxazosin standard, and placebo in patients with benign prostatic hyperplasia","volume":"38","author":"M Andersen","year":"2000","journal-title":"Eur Urol"},{"issue":"7","key":"pmen.0000494.ref042","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1038\/sj.npp.1301263","article-title":"There and back again: a tale of norepinephrine and drug addiction","volume":"32","author":"D Weinshenker","year":"2007","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"pmen.0000494.ref043","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.biopsych.2005.02.003","article-title":"Prazosin, an alpha-1 adrenergic antagonist, reduces cocaine-induced reinstatement of drug-seeking","volume":"57","author":"XY Zhang","year":"2005","journal-title":"Biol Psychiatry"},{"key":"pmen.0000494.ref044","author":"Hanson","year":"2025"},{"issue":"3","key":"pmen.0000494.ref045","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.psc.2023.04.006","article-title":"Substance Use Disorders in Women","volume":"46","author":"K Polak","year":"2023","journal-title":"Psychiatr Clin North Am"},{"issue":"5","key":"pmen.0000494.ref046","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/acer.12703","article-title":"A pilot trial of prazosin, an alpha-1 adrenergic antagonist, for comorbid alcohol dependence and posttraumatic stress disorder","volume":"39","author":"TL Simpson","year":"2015","journal-title":"Alcohol Clin Exp Res"},{"key":"pmen.0000494.ref047"}],"container-title":["PLOS Mental Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmen.0000494","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T18:30:04Z","timestamp":1763577004000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmen.0000494"}},"subtitle":[],"editor":[{"given":"Renato","family":"de Filippis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":47,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmen.0000494","relation":{},"ISSN":["2837-8156"],"issn-type":[{"value":"2837-8156","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]}}}